HEART FAILURE WITH PRESERVED EJECTION FRACTION: THERAPEUTIC STRATEGIES AND CURRENT PERSPECTIVES

Authors

  • Ryan Rafael Barros de Macedo Author
  • Filipe Victor Duarte Monteiro Author
  • Thiago Benitez Ribeiro Author
  • José Ricardo dos Santos Author
  • Giovanna Camargo dos Santos Author
  • Fernando Gomes Costa Author
  • Julle Anne de Deus Silva Author
  • Mateus Gomes de Barros Author
  • Luana Monteiro dos Santos Author
  • Ronaldo Antunes Barros Author
  • Isabela Vitória Grasso Author
  • Almiro Sadao Massuda Filho Author

DOI:

https://doi.org/10.56238/ERR01v10n4-013

Keywords:

Heart Failure with Preserved Ejection Fraction, Diagnosis, Treatment

Abstract

The heart is an adaptive organ that responds to diverse physiological and pathological stimuli. In heart failure with preserved ejection fraction (HFpEF), these adaptations exhibit specific characteristics, reflecting alterations in diastolic function and ventricular remodeling. The general objective of this study was to consolidate and critically analyze the current scientific evidence on HFpEF, addressing its pathophysiological bases, diagnostic challenges, and therapeutic strategies. The specific objective was to describe the main pharmacological and non-pharmacological therapies available, assessing their efficacy, clinical benefits, and limitations based on recent evidence. To this end, a narrative review of the literature was conducted, including studies evaluating pharmacological interventions, such as SGLT2 inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and metabolic modulators, as well as non-pharmacological approaches, prioritizing clinical trials, systematic reviews, and meta-analyses with relevant clinical outcomes. The therapeutic strategies analyzed showed a reduction in hospitalizations, improved functional capacity, and symptom control, highlighting the importance of an individualized approach based on patient characteristics and updated guidelines. The conclusion is that the management of HFpEF requires the integration of pharmacological and nonpharmacological therapies, with the potential to improve clinical outcomes and quality of life. Further studies are needed to optimize treatment for different patient profiles.

Downloads

Download data is not yet available.

References

1. NASSIF, M. E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nature Medicine, [S.l.], v. 27, n. 11, p. 1954–1960, nov. 2021.

DOI: 10.1038/s41591-021-01536-x. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34711976/

2. ANKER, S. D. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine, [S.l.], v. 385, n. 16, p. 1451-1461, 14 out. 2021. DOI: 10.1056/NEJMoa2107038. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34449189/

3. OMOTE, Kazunori; VERBRUGGE, Frederik H.; BORLAUG, Barry A. Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies. Annual Review of Medicine, v. 73, p. 321-337, 2022.

4. PEIKERT, A. et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circulation: Heart Failure, [S.l.], v. 15, n. 10, p. e010080, out. 2022. DOI: 10.1161/CIRCHEARTFAILURE.122.010080. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36029467/

5. ARNOLD, Suzanne V. et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, v. 11, n. 8, p. 893-900, 2023.

6. BORLAUG, Barry A. et al. Heart Failure With Preserved Ejection Fraction: JACC Scientific Statement. Journal of the American College of Cardiology, v. 81, n. 18, p. 1810-1834, 2023.

7. FAUCHIER, Laurent; BISSON, Arnaud; BODIN, Alexandre. Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions. BMC Medicine, v. 21, n. 1, p. 54, 2023.

8. LAM, C. S. P.; HO, J. E. Do we need dedicated heart failure with preserved ejection fraction clinics? European Heart Journal, [S.l.], v. 44, n. 17, p. 1557-1559, 1 maio 2023. DOI: 10.1093/eurheartj/ehad172. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36988191/

9. ASSMUS, B. et al. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clinical Research in Cardiology, [S.l.], v. 113, n. 9, p. 1287–1305, set. 2024. DOI: 10.1007/s00392-024-02396-4. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38602566/

10. KADDOURA, R. et al. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis. Current Problems in Cardiology, [S.l.], v. 49, n. 3, p. 102376, mar. 2024. DOI: 10.1016/j.cpcardiol.2024.102376. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38184132/

11. SILVA-CARDOSO, J. et al. A Portuguese expert panel position paper on the management of heart failure with preserved ejection fraction – Part I: Pathophysiology, diagnosis and treatment. Revista Portuguesa de Cardiologia, [S.l.], v. 44, n. 4, p. 233-243, abr. 2025. DOI: 10.1016/j.repc.2024.11.011. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39978763/

12. SILVA-CARDOSO, J. et al. A Portuguese expert panel position paper on the management of heart failure with preserved ejection fraction – Part II: Unmet needs and organization of care in Portugal. Revista Portuguesa de Cardiologia, [S.l.], v. 44, n. 5, p. 291-302, mai. 2025. DOI: 10.1016/j.repc.2024.12.004. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40057186/

13. FERREIRA, João Pedro et al. Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction: The SOGALDI-PEF Trial. Journal of the American College of Cardiology, [S.l.], v. 86, n. 5, p. 320-333, 5 ago. 2025. DOI: 10.1016/j.jacc.2025.05.033 Disponível em: https://pubmed.ncbi.nlm.nih.gov/40738559/

14. BARROS, Fernando Colares et al. Prognostic Applications of Current Clinical Scores in Heart Failure with Preserved Ejection Fraction: A Prospective Cohort Study. Arquivos Brasileiros de Cardiologia, [S.l.], v. 122, n. 6, e20240852, maio 2025. DOI: 10.36660/abc.20240852 Disponível em: https://pubmed.ncbi.nlm.nih.gov/40531679/

15. MIRZAI, Saeid et al. Aerobic, Resistance, and Specialized Exercise Training in Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review. Heart Failure Reviews, [S.l.], v. 30, n. 5, p. 1015-1034, set. 2025. DOI: 10.1007/s10741-025-10526-x Disponível em: https://pubmed.ncbi.nlm.nih.gov/40372567/

16. CINTI, F. et al. The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?. Cardiovascular Diabetology, [S.l.], v. 24, n. 1, p. 208, 14 maio 2025. DOI: 10.1186/s12933-025-02767-9 Disponível em: https://pubmed.ncbi.nlm.nih.gov/40369599/

17. OVCHINNIKOV, A. et al. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovascular Diabetology, [S.l.], v. 24, n. 1, p. 196, 9 maio 2025. DOI: 10.1186/s12933-025-02756-y Disponível em: https://pubmed.ncbi.nlm.nih.gov/40346546/

18. VRANKEN, N. P. A. et al. Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction. Cardiovascular Diabetology, [S.l.], v. 24, n. 1, p. 156, 5 abril 2025. DOI: 10.1186/s12933-025-02708-6 Disponível em: https://pubmed.ncbi.nlm.nih.gov/40188061/

19. DASTJERDI, P. et al. Liver biomarkers as predictors of prognosis in heart failure with preserved ejection fraction: a systematic review and meta-analysis. BMC Cardiovascular Disorders, [S.l.], v. 25, n. 1, p. 244, 2 abril 2025. DOI: 10.1186/s12872-025-04647-2 Disponível em: https://pubmed.ncbi.nlm.nih.gov/40175926/

20. PEIKERT, A. et al. Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial. European Heart Journal, [S.l.], v. 46, n. 25, p. 2372–2390, jul. 2025. DOI: 10.1093/eurheartj/ehaf057. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39873282/

21. PATON, M. F. et al. Echocardiography reporting in heart failure with preserved ejection fraction: Delphi consensus study. Open Heart, [S.l.], v. 12, n. 1, e003063, 28 mar. 2025. DOI: 10.1136/openhrt-2024-003063. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40154975/

22. LI, H. et al. Impact of exercise training on exercise tolerance, cardiac function and quality of life in individuals with heart failure and preserved ejection fraction: a systematic review and meta-analysis. BMC Cardiovascular Disorders, [S.l.], v. 25, n. 1, p. 217, mar. 2025. DOI: 10.1186/s12872-025-04649-0. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40133870/

23. MENGHOUM, N. et al. Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. Cardiovascular Diabetology, [S.l.], v. 24, n. 1, p. 134, 22 mar. 2025. DOI: 10.1186/s12933-025-02688-7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40121452/

24. HERRMANN, Ester Judith et al. Case series evaluating the relationship of SGLT2 inhibition to pulmonary artery pressure and non-invasive cardiopulmonary parameters in HFpEF/HFmrEF patients—a pilot study. Sensors (Basel), [S.l.], v. 25, n. 3, p. 605, 21 jan. 2025. DOI: 10.3390/s25030605. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39943245/

25. LEONE, D. et al. Heart failure with preserved ejection fraction: from echocardiographic characteristics to a cardiovascular damage score in a high-risk hypertensive population. Journal of Hypertension, [S.l.], v. 43, n. 4, p. 606–614, abr. 2025. DOI: 10.1097/HJH.0000000000003942. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39791437/

26. PACKER, Milton et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, [S.l.], v. 392, n. 5, p. 427–437, 30 jan. 2025. DOI: 10.1056/NEJMoa2410027. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39555826/

27. BEGHINI, A. et al. 2024 update in heart failure. ESC Heart Failure, [S.l.], v. 12, n. 1, p. 8–42, fev. 2025. DOI: 10.1002/ehf2.14857. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38806171/

28. MCDONAGH, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, Oxford, v. 42, n. 36, p. 3599-3726, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34447992/

29. HEIDENREICH, P. A. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, New York, v. 79, n. 17, p. e263-e421, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35363499/

30. BOCCHI, E. A. et al. Atualização da Diretriz Brasileira de Insuficiência Cardíaca – 2022. Arquivos Brasileiros de Cardiologia, São Paulo, v. 119, n. 3, p. 541-632, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30379264/

31. ORGANIZAÇÃO MUNDIAL DA SAÚDE (OMS). Cardiovascular diseases (CVDs). In: WHO – World Health Organization. [S.l.: s.n.], 31 jul. 2025. Disponível em: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29?utm_

32.ASHFAQ, A. et al. Role of cardiac rehabilitation in heart failure with preserved ejection fraction (HFpEF): a systematic review of clinical and functional outcomes. Frontiers in Cardiovascular Medicine, v. 12, p. 1545307, 2025. Disponível em: https://doi.org/10.3389/fcvm.2025.1545307. Acesso em: 3 set. 2025.

33.HEART LUNG CIRC. 2024 Australia–New Zealand expert consensus statement on cardiac amyloidosis. Heart, Lung and Circulation, v. 33, n. 4, p. e25-e34, 2024. Disponível em: https://doi.org/10.1016/j.hlc.2024.01.001. Acesso em: 3 set. 2025.

34.GEVAERT, A. et al. Training in HFpEF: exercise for the “win”? European Society of Cardiology, 2025. Disponível em: https://www.escardio.org/Sub-specialty-communities/European-Association-of-Preventive-Cardiology-%28EAPC%29/News/training-in-hfpef. Acesso em: 3 set. 2025.

35. AMERICAN HEART ASSOCIATION (AHA); AMERICAN COLLEGE OF CARDIOLOGY (ACC); HEART FAILURE SOCIETY OF AMERICA (HFSA). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. 2022. Disponível em: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063?utm_source

36. SOCIEDADE BRASILEIRA DE CARDIOLOGIA (SBC). Diretrizes Brasileiras de Insuficiência Cardíaca. 2022. Disponível em: http://publicacoes.cardiol.br/portal/abc/portugues/2018/v11103/pdf/11103021.pdf

37. BRASIL. Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC). Relatório de Recomendação nº 476, de 2024. Insuficiência cardíaca com fração de ejeção preservada: avaliação de tecnologias em saúde.

38. DANZMANN, L. C. et al. Terapia fundamental da insuficiência cardíaca com fração de ejeção preservada em 2022. ABC Heart Failure & Cardiomyopathy, v. 2, n. 1, p. 55–63, 2022. Disponível em: https://www.abcheartfailure.org/wp-content/uploads/articles_xml/2764-3107-abchf-002-01-0055/2764-3107-abchf-002-01-0055-pt.pdf

Downloads

Published

2025-09-10

Issue

Vol. 10 No. 4 (2025)

Section

Articles

How to Cite

HEART FAILURE WITH PRESERVED EJECTION FRACTION: THERAPEUTIC STRATEGIES AND CURRENT PERSPECTIVES. (2025). ERR01, 10(4), e7983 . https://doi.org/10.56238/ERR01v10n4-013